Kesang Li

Development of T Cells Redirected to Glypican-3 for the Treatment of Hepatocellular Carcinoma

Huiping Gao, Kesang Li, Hong Tu et al. · Clinical Cancer Research · 2014 · 308 citations

Life Sciences, Immunology, Oncology +12

Circular RNA circFGFR1 promotes progression and anti-PD-1 resistance by sponging miR-381-3p in non-small cell lung cancer cells

Pengfei Zhang, Xu Pei, Kesang Li et al. · Molecular Cancer · 2019 · 282 citations · Full text

Medicine, Cancer Biology, Oncology +17

Development of T cells carrying two complementary chimeric antigen receptors against glypican-3 and asialoglycoprotein receptor 1 for the treatment of hepatocellular carcinoma

Cheng Chen, Kesang Li, Hua Jiang et al. · Cancer Immunology Immunotherapy · 2016 · 110 citations · Full text

Medicine, Immunology, Oncology +17

SNHG22 overexpression indicates poor prognosis and induces chemotherapy resistance via the miR-2467/Gal-1 signaling pathway in epithelial ovarian carcinoma

Pengfei Zhang, Jing Wu, J. L. Luo et al. · Aging · 2019 · 52 citations · Full text

Medicine, Molecular Biology, Oncology +17

An EpCAM/CD3 bispecific antibody efficiently eliminates hepatocellular carcinoma cells with limited galectin-1 expression

Pengfei Zhang, Bizhi Shi, Huiping Gao et al. · Cancer Immunology Immunotherapy · 2013 · 47 citations · Full text

Medicine, Cancer Biology, Oncology +16